

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration Center for Drug Evaluation and Research Office of Pharmaceutical Quality Office of Surveillance Division of Quality Surveillance Assessment 10903 New Hampshire Avenue Building 51, Room 4316 Silver Spring, MD 20993 TELEPHONE: (301) 796-3254 FAX: (301) 847-8742

04/29/2016

Daicel Chiral Technologies
Phase-II,Lab-7, IKP Knowledge Park
Genome Valley, Turkapally Village
Shameerpet, Ranga Reddy, Hyderabad, Andhra Pradesh, IN

Reference: Inspection Date(s): 02/08/2016 - 02/10/2016

Location: Daicel Chiral Technologies

Phase-II,Lab-7, IKP Knowledge Park Genome Valley, Turkapally Village Shameerpet, Ranga Reddy, Hyderabad, 500 078, IN

Dear Dr.Ch.Lakshmi Narayan,

We are enclosing a copy of the establishment inspection report (EIR) for the inspection that the U.S. Food and Drug Administration (FDA) conducted at your premises on the referenced locale and date(s). When the Agency concludes that an inspection is "closed" under 21 CFR 20.64(d)(3), it will release a copy of the EIR to the inspected establishment. This procedure is applicable to EIRs for inspections completed on or after April 1, 1997.

The Agency continually works to make its regulatory process and activities more transparent to the regulated industry. Releasing this EIR to you is part of this effort. The copy being provided to you comprises the narrative portion of the report; it may reflect redactions made by the Agency in accordance with the Freedom of Information Act (FOIA) and 21 CFR Part 20. This, however, does not preclude you from requesting additional information under FOIA.

If there is any question about the released information, feel free to contact me at 240-402-6594.

For more information on the U.S. FDA, please visit our website at www.fda.gov.

Sincerely,

Jeneur Huft

FEI: 3009883135

Enclosure: Establishment Inspection Report (EIR)